➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: August 3, 2020

DrugPatentWatch Database Preview

Golimumab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for golimumab

Identify potential brand extensions & biosimilar entrants

Vlaams Instituut voor Biotechnologie (VIB); Merck Sharp & Dohme (MSD)Phase 3
David DrobnePhase 4
Bio-Thera SolutionsPhase 1

See all golimumab clinical trials

Recent Litigation for golimumab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
ABBVIE INC. v. SANDOZ INC.2018-08-10
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06

See all golimumab litigation

PTAB Litigation

See all golimumab litigation

Pharmacology for golimumab

Patent Text Search: US Patents for golimumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for golimumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2020505 Lithuania   Start Trial PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216
2020 00011 Denmark   Start Trial PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218
90062-2 Sweden   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196 20170627
C1057 France   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
2017000101 Germany   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
2017038 Lithuania   Start Trial PRODUCT NAME: SARILUMABAS; REGISTRATION NO/DATE: EU/1/17/1196 20170623
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.